Erin Long
Research Subjects
Research Interests
Erin Long has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Abhinandan Ranganathan
Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute, Vancouver, British Columbia, Canada
15 shared publications - Amy Short
ME Therapeutics Inc. Vancouver, British Columbia, Canada
15 shared publications - Andrew Gordon Robertson
Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency. Vancouver, British Columbia, Canada
15 shared publications - Brad H. Nelson
Deeley Research Centre, British Columbia Cancer - Victoria, University of British Columbia, Vancouver BC, Canada
15 shared publications - Danielle L. Krebs
Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute, Vancouver, British Columbia, Canada
15 shared publications - Israel Matos
Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute , 2350 Health Sciences Mall, Vancouver, British Columbia , V6T 1Z3
15 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised and G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised and G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S4 shows that G-CSF and G-CSFR signaling inhibit DC development and activation, in DCs derived in a OP9-DLL1 co-culture system.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S1 shows the characterization of MT and MTG-CSF-/- cell lines and tumors, including surface protein expression, tumor volume/weight, and immune cell subset content. Composition of immune cells in blood and spleen of MT and MTG-CSF-/- mice is also shown.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S3 shows deep phenotyping of Neut/MDSCs and B cells in the bone marrow of mice bearing MT or MTG-CSF-/- tumors, using FlowSOM applied in tSNE maps.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S3 shows deep phenotyping of Neut/MDSCs and B cells in the bone marrow of mice bearing MT or MTG-CSF-/- tumors, using FlowSOM applied in tSNE maps.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised and G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Supplementary Figure S2 compares the immune cell content in peripheral blood and spleens from immunocompetent, immunocompromised and G-CSFR-/- mice harboring MT or MTG-CSF-/- tumors.